Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pimecrolimus
Drug ID BADD_D01773
Description Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Indications and Usage For treatment of mild to moderate atopic dermatitis.
Marketing Status approved; investigational
ATC Code D11AH02
DrugBank ID DB00337
KEGG ID D05480
MeSH ID C117268
PubChem ID 6447131
TTD Drug ID D0Z4UN
NDC Product Code 55486-1585; 68682-112; 62227-004; 68254-0014; 0187-5102; 0591-2944; 62227-024; 65727-045; 0187-5101; 53296-0115; 0187-5100; 68682-110; 68462-609; 68682-111; 51552-1620; 16436-0115; 0187-5103
UNII 7KYV510875
Synonyms pimecrolimus | 33-epi-chloro-33-desoxyascomycin | SDZ ASM 981 | SDZ-ASM-981 | ASM 981 | Elidel
Chemical Information
Molecular Formula C43H68ClNO11
CAS Registry Number 137071-32-0
SMILES CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C 4)OC)Cl)C)O)C)OC)OC)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Accident12.01.08.001--Not Available
Acne23.02.01.001--Not Available
Alcohol intolerance14.02.01.001--
Alopecia23.02.02.0010.000700%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angiocentric lymphoma16.17.04.002; 01.11.04.002--Not Available
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001--Not Available
Application site erythema23.03.06.005; 12.07.01.001; 08.02.01.001--Not Available
Application site irritation12.07.01.003; 08.02.01.003--Not Available
Application site pain12.07.01.004; 08.02.01.0040.001586%Not Available
Application site pruritus23.03.12.004; 12.07.01.005; 08.02.01.005--Not Available
Application site rash08.02.01.016; 23.03.13.008; 12.07.01.0160.001586%Not Available
Application site reaction12.07.01.006; 08.02.01.006--Not Available
Arthralgia15.01.02.001--
Asthma22.03.01.002; 10.01.03.0100.000466%Not Available
Back pain15.03.04.005--
Basal cell carcinoma23.08.02.001; 16.03.02.001--Not Available
Blister23.03.01.001; 12.01.06.0020.001586%Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Burning sensation17.02.06.001; 08.01.09.0290.000466%Not Available
Chest pain02.02.02.011; 22.12.02.003; 08.01.08.0020.000466%Not Available
Colon cancer16.13.01.001; 07.21.01.001--Not Available
Condition aggravated08.01.03.0040.000700%Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cough22.02.03.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages